Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM), a prominent Indian pharmaceutical company has announced a strategic non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Ltd., aimed at introducing Vonoprazan in the Indian market under the brand name “Vonzai.” This collaboration marks a significant step forward in the treatment of Gastroesophageal Reflux Disease (GERD) and related disorders.

Vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was initially discovered and developed by Takeda. This innovative drug operates by reversibly and competitively inhibiting H+,K+-ATPase activity, leading to effective gastric acid suppression and elevated serum gastrin levels. The introduction of Vonoprazan provides a new therapeutic option for Indian patients suffering from reflux esophagitis and other related conditions.

In India, Vonoprazan is approved for multiple indications, including the treatment of gastric ulcers (GU) and duodenal ulcers (DU), prevention of ulcer recurrence during the use of low-dose aspirin or NSAIDs, and as an adjunct therapy for the eradication of H. pylori.

Dr. Vikas Gupta, Chief Executive Officer of Alkem Laboratories, commented on the partnership, stating, “Alkem’s strong presence in the gastrointestinal segment will be further enhanced by this collaboration with Takeda. Vonoprazan’s novel mechanism of action will allow us to better serve the large number of patients in India dealing with gastro-related health issues.”

Also Read: Sloth Fever: A Rising Global Health Threat and India’s Proactive Response

Celebrating 50 years of delivering high-quality medicines to patients, Alkem Laboratories Ltd. is the fifth-largest pharmaceutical company in India, with a robust portfolio that includes therapies for anti-infectives, gastrointestinal issues, pain management, and chronic conditions like diabetes, neurology, and cardiology. The company operates 19 state-of-the-art manufacturing facilities and advanced R&D centers across India and the US, focusing on the development of generic formulations, APIs, and biosimilars. With a global presence spanning the US, Latin America, Australia, and Asia, the organization remains committed to “Inspiring Healthier Lives” through its innovative and patient-focused approach.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.